We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management...
Information on taking, submitting and processing samples which potentially contain MPXV.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Meeting minutes taken from meetings of the Commission on Human Medicines' Vaccine Benefit Risk Expert Working Group (VBREWG) between 25 August 2020 and 5 May 2023.
Guidance for the veterinary pharmaceutical industry on the production and submission of the Summary of Product Characteristics (SPCs) and product literature mock-ups.
Explainer for the pharmaceutical industry on the implementation of Pharmacovigilance requirements during the transition time from the date the revised VMR have effect in GB to 17 May 2027.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
Prescribing or supplying veterinary medicines including requirements for registration and inspection of premises.
Details of the suspension of the marketing authorisation of Levothyroxine 100 microgram tablets, including MHRA investigations.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).